Tofacitinib
Tofacitinib is an active ingredient of the class «immunosuppressive drug».
Chemical compound
Boxed warning (US label)
SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS • Increased risk of serious bacterial, fungal, viral, and…
What it is used for
- Polyarthritis
- Osteoarthritis susceptibility 1
- Alopecia areata
- Bald head
- Arthritis
- Ulcerative colitis
- Rheumatoid arthritis
- Psoriatic arthritis
XELJANZ tablets and XELJANZ XR are indicated for the treatment of adult patients with: • Moderately to severely active rheumatoid arthritis (RA), who have had an inadequate response or intolerance to one or more TNF blockers. • Active psoriatic arthritis (PsA), who have had an inadequate response…
Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying…
How it works
- Janus Kinase (JAK) inhibitor
Class: immunosuppressive drug
Common side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: • Serious Infections • Increased Risk of Mortality • Malignancy and Lymphoproliferative Disorders • Major Adverse Cardiovascular Events • Thrombosis • Gastrointestinal Perforations • Hypersensitivity Reactions •…
Pregnancy and breastfeeding
The available data with XELJANZ (tablets and oral solution) and XELJANZ XR (extended-release tablets) from a pregnancy exposure registry that enrolled 11 exposed pregnant females, pharmacovigilance, and published literature are insufficient to draw…
Brand names
United States
Xeljanz · Xeljanz XR
European Union
Xeljanz
Canada
Apo-Tofacitinib · Auro-Tofacitinib · Devatis Tofacitinib · Jamp Tofacitinib · Pms-Tofacitinib · Sandoz Tofacitinib · Taro-Tofacitinib · Taro-Tofacitinib XR · Xeljanz · Xeljanz XR
Approval status
- US Food and Drug Administration
- prescription · since 2012
- European Medicines Agency
- authorised · since 2017
- Health Canada
- prescription · marketed
- First approval anywhere
- 2012
Codes
- ATC
- L04AA29, L04AF01
- RxNorm CUI
- 1357536
- ChEMBL
- CHEMBL221959
- PubChem CID
- 9926791
- UNII
- 87LA6FU830
- Wikidata
- Q3530324
Frequently asked questions
What is Tofacitinib used for?
Tofacitinib is used for: Polyarthritis, Osteoarthritis susceptibility 1, Alopecia areata, Bald head, Arthritis, Ulcerative colitis, Rheumatoid arthritis, and Psoriatic arthritis.
What kind of medicine is Tofacitinib?
Tofacitinib is an active ingredient of the class «immunosuppressive drug».
What are the brand names of Tofacitinib?
Brand names of Tofacitinib include Xeljanz, Xeljanz XR, Apo-Tofacitinib, Auro-Tofacitinib, Devatis Tofacitinib, Jamp Tofacitinib, Pms-Tofacitinib, and Sandoz Tofacitinib.
Medicines in the same class
- Sirolimus
- Adalimumab
- Everolimus
- Leflunomide
- Fingolimod
- Cladribine
- Apremilast
- Teriflunomide
- Mycophenolate mofetil
Sources and licences
- ChEMBL (CC BY-SA 3.0)
- Wikidata (CC0 1.0)
- openFDA / DailyMed (public domain)
- European Medicines Agency (reuse with acknowledgement)
- Health Canada Drug Product Database (Open Government Licence – Canada)